Browse site A – Z

Your views

Your Views

Your feedback is vital to us as we continue to increase the quality of our services.

Your views

You are here:

Date: 24 September 2023

Time: 08:45

Some of our HIV research trials

Metabolic study

Assessing the longitudinal relationship between lipodystrophy and very low-density lipoprotein (VLDL) metabolism in human immunodeficiency virus (HIV) infected patients.

Kivexa sub-study

A comparison of subcutaneous fat tissue from patients who have been taking a regimen containing abacavir/lamivudine/efavirenz for 6 months and 18-24 months with those on tenofovir/emtricitabine/efavirenz for 6 months and 18-24 months.

ASSERT study

A multi-national, randomised, controlled trial assessing the comparative efficacy of kivexa and truvada administered with efavirenz in antiretroviral-naïve, human immunodeficiency virus-1 (HIV-1) infected subjects.

ROCKET study

A randomised, controlled study to assess the effect on lipid profile of switching from a stable highly active antiretroviral therapy (HAART) regimen of fixed dose kivexa plus efavirenz, to once daily atripla in adult HIV-1 infected subjects with raised cholesterol.

ONCE study

A multi-national, randomised, controlled trial comparing tenofovir/efavirenz with atripla in patients infected with HIV.

POEM study

A multi-centre, prospective observational study of the safety of maraviroc used with optimised background therapy in treatment-experienced HIV-1 infected patients.

Elvitegravir study

A multi-centre, randomised, double-blind, double-dummy study of the safety and efficacy of Ritonavir-boosted Elvitegravir versus Raltegravir, each administered with a background regimen in HIV-1 infected, antiretroviral treatment-experienced adults.

Tubercles Bacillus or TB vaccine study

In collaboration with Oxford University in assessing the safety and efficacy of a candidate TB vaccine in HIV infected patients.

UK Register of HIV seroconverters

An observational study of HIV infected persons in the UK for whom the time of HIV seroconversion is well estimated.

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.